Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Yusman Manchanda"'
Autor:
Emma Rose McGlone, Yusman Manchanda, Ben Jones, Phil Pickford, Asuka Inoue, David Carling, Stephen R. Bloom, Tricia Tan, Alejandra Tomas
Publikováno v:
Molecular Metabolism, Vol 53, Iss , Pp 101296- (2021)
Objectives: Receptor Activity-Modifying Protein 2 (RAMP2) is a chaperone protein which allosterically binds to and interacts with the glucagon receptor (GCGR). The aims of this study were to investigate the effects of RAMP2 on GCGR trafficking and si
Externí odkaz:
https://doaj.org/article/260c126240254cdf851adc98b9aeadbb
Autor:
Zijian Fang, Shiqian Chen, Yusman Manchanda, Stavroula Bitsi, Philip Pickford, Alessia David, Maria M. Shchepinova, Ivan R. Corrêa Jr, David J. Hodson, Johannes Broichhagen, Edward W. Tate, Frank Reimann, Victoria Salem, Guy A. Rutter, Tricia Tan, Stephen R. Bloom, Alejandra Tomas, Ben Jones
Publikováno v:
International Journal of Molecular Sciences, Vol 21, Iss 21, p 8404 (2020)
The glucagon-like peptide-1 receptor (GLP-1R) is an important regulator of blood glucose homeostasis. Ligand-specific differences in membrane trafficking of the GLP-1R influence its signalling properties and therapeutic potential in type 2 diabetes.
Externí odkaz:
https://doaj.org/article/cf28e43f0062455ba4ca407ebf27a774
Autor:
Stavroula Bitsi, Liliane El Eid, Yusman Manchanda, Affiong I. Oqua, Nimco Mohamed, Ben Hansen, Kinga Suba, Guy A. Rutter, Victoria Salem, Ben Jones, Alejandra Tomas
Publikováno v:
Science Advances. 9
The glucagon-like peptide-1 receptor (GLP-1R) is a major type 2 diabetes therapeutic target. Stimulated GLP-1Rs are rapidly desensitized by β-arrestins, scaffolding proteins that not only terminate G protein interactions but also act as independent
Autor:
Yusman Manchanda, Stavroula Bitsi, Shiqian Chen, Johannes Broichhagen, Jorge Bernardino de la Serna, Ben Jones, Alejandra Tomas
The incretin receptors, glucagon-like peptide-1 receptor (GLP-1R) and glucose-dependent insulinotropic polypeptide receptor (GIPR), are prime therapeutic targets for the treatment of type 2 diabetes (T2D) and obesity. They are expressed in pancreatic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9e73f2884551c1ef1fe6a6d157a779cb
http://hdl.handle.net/10044/1/102944
http://hdl.handle.net/10044/1/102944
Autor:
Yusman Manchanda, Stavroula Bitsi, Shiqian Chen, Johannes Broichhagen, Jorge Bernardino de la Serna, Ben Jones, Alejandra Tomas
The incretin receptors, glucagon-like peptide-1 receptor (GLP-1R) and glucose-dependent insulinotropic polypeptide receptor (GIPR), are class B GPCRs and prime therapeutic targets for the treatment of type 2 diabetes (T2D) and obesity. They are expre
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7458ee6c95dc9a73fb4756c2689ade3f
https://doi.org/10.1101/2022.08.17.504231
https://doi.org/10.1101/2022.08.17.504231
Autor:
Ben Jones, Vinod Burade, Elina Akalestou, Yusman Manchanda, Zenouska Ramchunder, Gaëlle Carrat, Marie‐Sophie Nguyen‐Tu, Piero Marchetti, Lorenzo Piemonti, Isabelle Leclerc, Rajamannar Thennati, Tina Vilsboll, Bernard Thorens, Alejandra Tomas, Guy A. Rutter
Publikováno v:
Jones, B, Burade, V, Akalestou, E, Manchanda, Y, Ramchunder, Z, Carrat, G, Nguyen-Tu, M-S, Marchetti, P, Piemonti, L, Leclerc, I, Thennati, R, Vilsboll, T, Thorens, B, Tomas, A & Rutter, G A 2022, ' In vivo and in vitro characterization of GL0034, a novel long-acting glucagon-like peptide-1 receptor agonist ', Diabetes, Obesity and Metabolism, vol. 24, no. 11, pp. 2090-2101 . https://doi.org/10.1111/dom.14794
Aims: To describe the in vitro characteristics and antidiabetic in vivo efficacy of the novel glucagon-like peptide-1 receptor agonist (GLP-1RA) GL0034. Materials and Methods: Glucagon-like peptide-1 receptor (GLP-1R) kinetic binding parameters, cycl
Autor:
null Ben Jones, null Vinod Burade, null Elina Akalestou, null Yusman Manchanda, null Zenouska Ramchunder, null Gaëlle Carrat, null Marie‐Sophie Nguyen‐Tu, null Piero Marchetti, null Lorenzo Piemonti, null Isabelle Leclerc, null Thennati Rajamannar, null Tina Vilsboll, null Bernard Thorens, null Alejandra Tomas, null Guy A. Rutter
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cae1e3f6ddfe65866b0e30704fe1c003
https://doi.org/10.1111/dom.14794/v2/response1
https://doi.org/10.1111/dom.14794/v2/response1
Autor:
Stavroula Bitsi, Yusman Manchanda, Liliane ElEid, Nimco Mohamed, Ben Hansen, Kinga Suba, Guy A. Rutter, Victoria Salem, Ben Jones, Alejandra Tomas
The glucagon-like peptide-1 receptor (GLP-1R) is a major therapeutic target in type 2 diabetes (T2D) and obesity. Following activation, GLP-1Rs are rapidly desensitised by β-arrestins, scaffolding proteins that terminate G protein interactions but a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c54864b84cea635fadb6d75807be2eb2
https://doi.org/10.1101/2022.04.21.489075
https://doi.org/10.1101/2022.04.21.489075
Publikováno v:
Current Opinion in Endocrine and Metabolic Research. 16:19-27
Pleiotropic signalling by G protein–coupled receptors is subject to spatiotemporal regulation, which allows precise control over a diverse range of cellular outputs. The glucagon-like peptide-1 receptor (GLP-1R), a class B G protein–coupled recep
Autor:
Alejandra Tomas, Zenouska Ramchunder, Yusman Manchanda, Edward W. Tate, Asuka Inoue, Guy A. Rutter, Maria M. Shchepinova, Ben Jones
Mini-G proteins are engineered thermostable variants of Gα subunits designed to specifically stabilise G protein-coupled receptors (GPCRs) in their active conformation for structural analyses. Due to their smaller size and ease of use, they have bec
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bb385a84524756ad5bfec81664c0c4b3
https://doi.org/10.1101/2021.11.24.469908
https://doi.org/10.1101/2021.11.24.469908